Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meindert N Sosef

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Histopathology|March 4, 2021
High CD8<sup>+</sup> tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapyWillem J Koemans, Jolanda M van Dieren, Jose G van den Berg, et al.
Annals of the New York Academy of Sciences|October 1, 2014
Therapeutic approaches to gastroesophageal junction adenocarcinomasRachel L G M Blom, Tatiana Bogush, Björn L D M Brücher, et al.
BMC Cancer|August 19, 2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsRuben T H M Larue, Lien Van De Voorde, Maaike Berbée, et al.
Trials|April 29, 2014
Preoperative inspiratory muscle training to prevent postoperative pulmonary complications in patients undergoing esophageal resection (PREPARE study): study protocol for a randomized controlled trialKarin Valkenet, Jaap Ca Trappenburg, Rik Gosselink, et al.
Annals of Surgical Oncology|October 23, 2025
Accuracy of Predicting Residual Disease and Disease Progression During Active Surveillance for Esophageal CancerSanjiv S G Gangaram Panday, David van Klaveren, Sjoerd M Lagarde, et al.
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Annals of Surgical Oncology|July 27, 2024
Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort StudyCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
JAMA Network Open|April 19, 2024
Nationwide Association of Surgical Performance of Minimally Invasive Esophagectomy With Patient OutcomesMirte H M Ketel, Bastiaan R Klarenbeek, Inger Abma, et al.
Annals of Surgery|May 25, 2026
Pathological Outcomes After Uncertain Response to Neoadjuvant Chemoradiotherapy in Esophageal CancerSanjiv S G Gangaram Panday, Dion In 't Veld, Bianca Mostert, et al.
BMC Cancer|February 8, 2018
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trialBo Jan Noordman, Bas P L Wijnhoven, Sjoerd M Lagarde, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Histopathology|March 4, 2021
High CD8<sup>+</sup> tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapyWillem J Koemans, Jolanda M van Dieren, Jose G van den Berg, et al.
Annals of the New York Academy of Sciences|October 1, 2014
Therapeutic approaches to gastroesophageal junction adenocarcinomasRachel L G M Blom, Tatiana Bogush, Björn L D M Brücher, et al.
BMC Cancer|August 19, 2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patientsRuben T H M Larue, Lien Van De Voorde, Maaike Berbée, et al.
Trials|April 29, 2014
Preoperative inspiratory muscle training to prevent postoperative pulmonary complications in patients undergoing esophageal resection (PREPARE study): study protocol for a randomized controlled trialKarin Valkenet, Jaap Ca Trappenburg, Rik Gosselink, et al.
Annals of Surgical Oncology|October 23, 2025
Accuracy of Predicting Residual Disease and Disease Progression During Active Surveillance for Esophageal CancerSanjiv S G Gangaram Panday, David van Klaveren, Sjoerd M Lagarde, et al.
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Annals of Surgical Oncology|July 27, 2024
Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort StudyCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
JAMA Network Open|April 19, 2024
Nationwide Association of Surgical Performance of Minimally Invasive Esophagectomy With Patient OutcomesMirte H M Ketel, Bastiaan R Klarenbeek, Inger Abma, et al.
Annals of Surgery|May 25, 2026
Pathological Outcomes After Uncertain Response to Neoadjuvant Chemoradiotherapy in Esophageal CancerSanjiv S G Gangaram Panday, Dion In 't Veld, Bianca Mostert, et al.
BMC Cancer|February 8, 2018
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trialBo Jan Noordman, Bas P L Wijnhoven, Sjoerd M Lagarde, et al.
Pageof 6